```html

Kala‑azar (Visceral Leishmaniasis) – Comprehensive Medical Guide

Overview

Kala‑azar, also known as visceral leishmaniasis (VL), is a life‑threatening parasitic disease caused by Leishmania donovani complex organisms. The parasites are transmitted to humans through the bite of infected female sandflies (genus Phlebotomus in the Old World and Lutzomyia in the New World).

The disease primarily affects the poorest, marginalized populations living in rural or peri‑urban settings where sandflies breed. It is endemic in South Asia (India, Bangladesh, Nepal), East Africa (Sudan, Ethiopia, Kenya), Brazil, and parts of the Mediterranean. According to the World Health Organization (WHO), an estimated 50,000–90,000 new cases occur each year, with a case‑fatality rate of 5–10 % when left untreated.<sup>[1] WHO, Leishmaniasis Fact Sheet 2023</sup>

Symptoms

Symptoms typically appear 2–6 months after infection, but the incubation period can be as short as weeks or as long as several years. The classic triad includes:

• Prolonged fever – often irregular, lasting weeks.
• Splenomegaly – marked enlargement of the spleen, causing left‑upper‑quadrant fullness or pain.
• Hepatomegaly – enlarged liver, sometimes palpable.

Additional clinical features may develop as the disease progresses:

Constitutional signs

• Weight loss & wasting (cachexia)
• Fatigue & generalized weakness
• Night sweats

Hematologic & immunologic signs

• Pancytopenia (low red cells, white cells, and platelets)
• Hyperpigmentation of skin (especially on the face and upper trunk)
• Recurrent infections due to immune suppression

Gastro‑intestinal & other organ involvement

• Abdominal distention from ascites
• Loss of appetite
• Fever spikes that may be confused with malaria or typhoid
• Rarely, involvement of the lungs, heart, or central nervous system (especially in immunocompromised patients)

Causes and Risk Factors

Etiology

Visceral leishmaniasis is caused by intracellular protozoa of the Leishmania donovani complex. After a sandfly bite, promastigotes are phagocytosed by macrophages, where they transform into amastigotes and multiply, spreading to the reticulo‑endothelial system (spleen, liver, bone marrow).

Key risk factors

• Geographic exposure: Living or traveling in endemic regions.
• Poverty & malnutrition: Undernourished individuals have weaker cell‑mediated immunity.
• Immunosuppression: HIV co‑infection dramatically increases susceptibility; co‑infection rates can exceed 30 % in some Indian districts.<sup>[2] CDC, HIV & Leishmania</sup>
• Occupational exposure: Agricultural workers, forest laborers, and military personnel who spend nights outdoors.
• Age: Children under 10 and adults over 50 are more likely to develop severe disease.
• Sex: Males are modestly more affected, likely due to occupational exposure.

Diagnosis

Because early symptoms mimic malaria, typhoid, or tuberculosis, a high index of suspicion is required in endemic areas. Diagnosis combines clinical evaluation with laboratory confirmation.

Laboratory tests

• Serology: rK39 rapid immunochromatographic test (detects antibodies) – >95 % sensitivity in South Asia, slightly lower in East Africa.<sup>[3] BMJ 2021</sup>
• Enzyme‑linked immunosorbent assay (ELISA): More quantitative, useful for monitoring treatment response.
• Direct agglutination test (DAT):** Highly sensitive but requires laboratory infrastructure.

Parasitological confirmation (gold standard)

• Microscopy: Demonstration of amastigotes in splenic, hepatic, or bone‑marrow aspirates. Splenic aspirates have the highest yield (>95 %) but carry a bleeding risk.
• Polymerase chain reaction (PCR): Detects Leishmania DNA in blood, tissue, or urine; useful for relapse monitoring.
• Culture: NNN (Novy–MacNeal–Nicolle) medium, rarely used clinically due to time constraints.

Other investigations

• Complete blood count (CBC) – often shows pancytopenia.
• Liver function tests – mild transaminase elevation.
• Urinalysis – proteinuria may occur.
• Chest X‑ray or abdominal ultrasound – to assess organomegaly and rule out other causes.

Treatment Options

The choice of therapy depends on the geographic region, drug availability, patient age, pregnancy status, and HIV co‑infection.

First‑line anti‑leishmanial drugs

• Liposomal amphotericin B (AmBisome): 3–5 mg/kg on days 1–5, 14, and 21 (total 21 mg/kg). >95 % cure rates; preferred for HIV‑positive patients and pregnant women.<sup>[4] WHO 2022 Guidelines</sup>
• Miltefosine: Oral 2.5 mg/kg/day for 28 days. Cure rates 90–95 % in South Asia but teratogenic; avoid in pregnancy.
• Sodium stibogluconate (SSG) or meglumine antimoniate: Pentavalent antimonials, 20 mg/kg/day for 30 days. Efficacy declining in India due to resistance (≈60 % cure). Used where alternative drugs are unavailable.

Combination regimens

In areas with high drug resistance, combinations such as AmBisome + miltefosine or SSG + paromomycin improve cure rates and shorten therapy.

Adjunctive care

• Blood transfusions for severe anemia.
• Platelet transfusion if platelet count <20 × 10⁹/L with bleeding.
• Nutritional rehabilitation (high‑protein diet, multivitamins).
• Management of co‑existing infections (e.g., antibiotics for bacterial sepsis).

Monitoring during treatment

• Weekly CBC and liver/kidney function tests.
• Clinical assessment of fever and organ size.
• Post‑treatment serology (rK39) may remain positive for months; PCR is more reliable for detecting relapse.

Living with Kala‑azar (Visceral Leishmaniasis)

Even after successful therapy, patients often need support to regain strength and prevent relapse.

Daily management tips

• Nutrition: Eat nutrient‑dense foods – lean protein (eggs, legumes), iron‑rich greens, vitamin‑C rich fruits to aid iron absorption.
• Hydration: Maintain adequate fluid intake; fever can cause dehydration.
• Rest and activity: Gradual return to normal activity over 4–6 weeks; avoid heavy labor until spleen size returns to normal.
• Follow‑up appointments: Attend all scheduled clinic visits for lab monitoring, especially in the first 3 months.
• Vaccinations: Keep immunizations up to date (e.g., pneumococcal, hepatitis B) because of transient immune suppression.
• Psychosocial support: Stigma can be an issue; connect with community health workers or support groups.

Special considerations

• Pregnancy: Liposomal amphotericin B is the drug of choice; avoid miltefosine.
• HIV co‑infection: Treat HIV concurrently, ensure ART adherence, and consider secondary prophylaxis (e.g., monthly amphotericin B) for 12 months after cure.<sup>[5] NIH HIV/Leishmania Consensus 2022</sup>

Prevention

Because the parasite is transmitted by sandflies, control strategies target both the vector and human exposure.

Vector control

• Insecticide‑treated nets (ITNs): Bed nets with long‑lasting insecticide reduce indoor sandfly bites.
• Indoor residual spraying (IRS): Application of DDT or pyrethroids in homes; especially effective in South Asia.
• Environmental management: Remove organic waste, animal shelters, and damp soil where sandflies breed.

Personal protective measures

• Wear long‑sleeved shirts and pants during dusk–dawn when sandflies are most active.
• Apply DEET‑based repellents (≥30 % concentration) to exposed skin.
• Use screened windows and doors; keep doors closed at night.

Health‑system interventions

• Early case detection through community health workers.
• Mass drug administration (MDA) in hyper‑endemic pockets (currently under research).
• Education campaigns about sandfly habits and disease signs.

Complications

If untreated or inadequately treated, Kala‑azar can lead to severe, sometimes fatal, complications:

• Severe anemia, leukopenia, thrombocytopenia → life‑threatening bleeding or secondary infections.
• Hepatosplenomegaly → splenic rupture (rare but catastrophic).
• Post‑Kala‑azar dermal leishmaniasis (PKDL): Hyperpigmented skin lesions that appear months to years after cure, especially common in Sudan and India.
• Secondary bacterial infections due to immune suppression.
• Relapse: Up to 10 % of treated patients in East Africa may relapse within 12 months.
• Co‑infection mortality: HIV–VL co‑infection carries a 20–30 % mortality rate if not aggressively managed.

When to Seek Emergency Care

References

1. World Health Organization. Leishmaniasis Fact Sheet. 2023. https://www.who.int
2. Centers for Disease Control and Prevention. Visceral Leishmaniasis (Kala‑azar) and HIV Coinfection. 2022. https://www.cdc.gov
3. Hasker E, et al. Diagnostic accuracy of the rK39 rapid test for visceral leishmaniasis: a systematic review. BMJ. 2021;372:n428.
4. World Health Organization. Guidelines for the treatment of leishmaniasis. 2022. https://apps.who.int
5. National Institutes of Health. HIV and Leishmania Co‑infection Consensus Statement. 2022. https://www.ncbi.nlm.nih.gov

```